Atopic dermatitis (AD) is a complex systemic disease characterized by high heterogeneity both at clinical and pathophysiology levels. While advances in drug development toward a more targeted approach are made, treatment and management of AD patients are still happening according to the one-size-fits-all approach. To enhance precision medicine in AD and improve care, identifying predicting factors of response to therapy driving tailored treatments will be of utmost importance. Here, we discuss the available evidence regarding predictive biomarkers, as well as their possible and still debated impact in clinical practice.
Enabling precision medicine with biomarkers of response to treatment in atopic dermatitis: where are we now? A narrative review
Giampiero Girolomoni
2025-01-01
Abstract
Atopic dermatitis (AD) is a complex systemic disease characterized by high heterogeneity both at clinical and pathophysiology levels. While advances in drug development toward a more targeted approach are made, treatment and management of AD patients are still happening according to the one-size-fits-all approach. To enhance precision medicine in AD and improve care, identifying predicting factors of response to therapy driving tailored treatments will be of utmost importance. Here, we discuss the available evidence regarding predictive biomarkers, as well as their possible and still debated impact in clinical practice.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Chiricozzi AD biomarkers Front Med 2025 (1).pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
7.36 MB
Formato
Adobe PDF
|
7.36 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
